Fri, May 30, 8:03 PM (19 days ago)
**Nutriband Inc. (NTRB) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $667,432 (up from $408,532 in Q1 2024) - **Net Loss:** $1,388,869 (improved from $1,898,077 in Q1 2024) - **Cash Flow:** Used $1,336,972 in operations (improved from $1,898,077 in Q1 2024) - **Cash Position:** $2,964,097 (down from $4,311,719 in Q1 2024) - **Working Capital:** $2,504,596 (down from $3,811,420 in Q1 2024) **Profit Margins & Expenses:** - **Gross Profit Margin:** Improved due to higher margins in sales mix. - **Operating Expenses:** $982,052 (down from $1,079,728 in Q1 2024) - **R&D Expenses:** $683,426 (down from $974,535 in Q1 2024) **Segment Performance:** - **Pocono Pharmaceuticals:** Revenue $667,432 (up from $408,532 in Q1 2024) - **4P Therapeutics:** No revenue (shift in focus and main contract wound down) **Trends & Uncertainties:** - Increased demand expected in the balance of the current year. - Substantial doubt about the ability to continue as a going concern is alleviated by the assessment of sufficient funds for operations. - Legal proceedings and economic uncertainties may impact future operations. **Future Operations:** - Continued focus on Aversa Fentanyl development. - Potential for additional equity offerings to raise capital. - Ongoing clinical trials and product development for abuse deterrent transdermal products. **Ticker:** NTRB **Note:** Amounts are in thousands, 000s.